1 ol and with allopurinol alone in controlling plasma uric acid.

2  Allopurinol inhibited the increase in fetal plasma uric acid and suppressed the fetal femoral vasoco

3 int was to compare the area under the serial plasma uric acid concentration curves during the first 9

4 nzyme produced a rapid and sharp decrease in plasma uric acid concentrations in all patients.

5          Despite cytoreductive chemotherapy, plasma uric acid concentrations remained low throughout

6 inol, a competitive inhibitor of XO, reduced plasma uric acid concentrations similarly in both groups

7                                      Time to plasma uric acid control in hyperuricemic patients was 4

8 rated more rapid control and lower levels of plasma uric acid in patients at high risk for tumor lysi

9      Rasburicase is effective in controlling plasma uric acid in pediatric patients with hematologic

10 eterm, difference = 1.7, 95% CI: -0.1, 3.4), plasma uric acid levels (for those born early preterm, d

11          Higher intake of fructose increases plasma uric acid levels and higher intake of vitamin C r

12                                    Moreover, plasma uric acid levels in mice fed the WD were decrease

13                        Primary end point was plasma uric acid levels of less than 6.0 mg/dL in months

14 % versus 12% reduction (P <.0001) of initial plasma uric acid levels.

15 centage of patients achieving or maintaining plasma uric acid &lt;/= 7.5 mg/dL during days 3 to 7.

16 isk for TLS, rasburicase provided control of plasma uric acid more rapidly than allopurinol.

17                                       Higher plasma uric acid (PUA) levels are associated with lower

18                Primary efficacy variable was plasma uric acid response rate defined as percentage of

19                                              Plasma uric acid response rate was 87% with rasburicase,

20                                 The level of plasma uric acid was found to be highly significantly in